We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
This Quarter
Est. Return
+18.47%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
+$705M
(+33%)
Cap. Flow
+$506M
Cap. Flow
% of AUM
17.82%
Top 10 Holdings %
Top 10 Hldgs %
58.91%
Holding
40
New
10
Increased
16
Reduced
5
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$132M |
| 2 |
Revolution Medicines
RVMD
|
+$86.4M |
| 3 |
Vaxcyte
PCVX
|
+$85.9M |
| 4 |
Arvinas
ARVN
|
+$73.6M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
+$54.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$90.7M |
| 2 |
AMAM
Ambrx Biopharma Inc
AMAM
|
+$62M |
| 3 |
AUTL
Autolus Therapeutics
AUTL
|
+$38.6M |
| 4 |
TG Therapeutics
TGTX
|
+$37.1M |
| 5 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$31.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cullinan Oncology
CGEM
$1.08B
| $23M | 0.81% |
+1,348,015
| New | +$20.8M |
|
27
Apogee Therapeutics
APGE
$10.1B
| $21.9M | 0.77% |
+330,000
| New | +$14.4M |
|
|
CMPS
28
Compass Pathways
CMPS
$1.59B
| $19.9M | 0.7% |
2,390,988
+125,000
| +6% | +$1.26M |
|
29
Vor Biopharma
VOR
$1.21B
| $15.3M | 0.54% |
322,865
| – | – |
|
30
Zentalis Pharmaceuticals
ZNTL
$347M
| $14.9M | 0.52% |
944,917
+544,917
| +136% | +$7.5M |
|
31
Agios Pharmaceuticals
AGIO
$1.89B
| $11.7M | 0.41% |
+400,000
| New | +$10.7M |
|
32
Caribou Biosciences
CRBU
$156M
| $11.2M | 0.39% |
2,172,620
-751,231
| -26% | -$4.63M |
|
|
CRGX
33
DELISTED
CARGO Therapeutics
CRGX
| $3.3M | 0.12% |
147,959
-185,374
| -56% | -$4.41M |
|
34
Kyverna Therapeutics
KYTX
$473M
| $1.24M | 0.04% |
+50,000
| New | +$1.4M |
|
|
JBIO
35
Jade Biosciences
JBIO
$1.3B
| – | – |
-4,092
| Closed | -$3.24M |
|
|
36
TG Therapeutics
TGTX
$7.46B
| – | – |
-2,171,419
| Closed | -$37.1M |
|
37
Zai Lab
ZLAB
$2.09B
| – | – |
-1,091,779
| Closed | -$29.8M |
|
|
AMAM
38
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
| – | – |
-150,000
| Closed | -$2.14M |
|
|
AMAM
39
DELISTED
Ambrx Biopharma Inc
AMAM
| – | – |
-4,352,689
| Closed | -$62M |
|
|
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-1,543,116
| Closed | -$90.7M |
|
Similar funds
KCM
DGI
FC
MCM
MCCA
SIA
SCA
SMFG
Paradigm Biocapital Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, Paradigm Biocapital Advisors held 40 positions worth $2.84B, up 33% from $2.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Paradigm Biocapital Advisors deployed $506M of net new capital in Q1 2024, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Sarepta Therapeutics: 1,078,346 shares worth $140M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Autolus Therapeutics, an estimated $38.6M trimmed.
- Paradigm Biocapital Advisors's largest Q1 2024 buy was Sarepta Therapeutics: 1,078,346 shares worth $140M.
- Paradigm Biocapital Advisors added most to Arvinas in Q1 2024, an estimated $73.6M increase.
- Paradigm Biocapital Advisors's biggest Q1 2024 reduction was Autolus Therapeutics, cutting an estimated $38.6M.
- Paradigm Biocapital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $90.7M.
- Paradigm Biocapital Advisors's ten largest holdings make up 59% of its $2.84B portfolio in Q1 2024.
- Paradigm Biocapital Advisors opened 10 new positions and closed 6 in Q1 2024.
- Paradigm Biocapital Advisors's portfolio value rose 33% quarter-over-quarter to $2.84B.
Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.